secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001789769-23-000090
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q3 net loss $67.4M; restructuring charges $46.3M; cash runway beyond 2026
--------------------------------------------------------------------------------

- Net loss $67.4M ($0.52 per share) vs $56.2M ($0.43) in Q3 2022.
- Cash, equivalents, restricted cash and marketable securities $184.5M, down from $260.9M at Dec 31, 2022.
- Restructuring and impairment charges of $46.3M in Q3 2023; none in prior year.
- R&D expenses dropped to $8.5M from $39.7M reflecting pipeline reprioritization.
- Cash runway expected beyond 2026; ITIL-306 Phase 1 data in NSCLC anticipated in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/0001789769-23-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/til-20231113.htm
  HTML page:      https://secwatch.observer/filing/0001789769-23-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer